AIDS Research Strategy Debate Continues As Funding Cuts Loom
NIH researchers don’t know exactly what will have the most impact – investigations into HIV treatments or cures – meaning it is difficult to determine where funding should be focused.
You may also be interested in...
FDA and advocates wait for OMB to clarify how the estimated 7.8% budget cut should be implemented, if it is enacted. Former agency officials say it could lead to hiring freezes and program delays.
CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.
Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.